GlassScriptPhysician profile
James Michael Allen
NPI 1063036150
$3,958.00
in general payments reported to CMS, 2019-2025
27 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.93 · 2022: $1,329 · 2023: $765 · 2024: $663 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,388.14 |
| Education | $158.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $630.87 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $529.42 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $521.46 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $315.56 | 2022-2025 | |
| Corium, LLC | $265.36 | 2023-2025 | Azstarys |
| Neos Therapeutics, LP | $167.77 | 2022-2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Avanir Pharmaceuticals, INC. | $163.26 | 2022 | |
| Neurocrine Biosciences, INC. | $140.35 | 2025 | |
| Indivior INC. | $140.26 | 2022-2023 | Perseris |
| Lundbeck LLC | $138.39 | 2022-2025 | Rexulti, Brintellix |
| Almatica Pharma LLC | $120.85 | 2024-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $118.72 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $98.95 | 2024-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $80.90 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $71.30 | 2022-2025 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $64.57 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $56.86 | 2024-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $48.44 | 2025 | Cobenfy |
| Eisai INC. | $38.60 | 2022 | |
| Bausch Health US, LLC | $33.27 | 2023-2024 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $30.66 | 2023-2024 | Quviviq |
| Aytu Biopharma, INC. | $23.13 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.63 | 2022 | |
| Merck Sharp & Dohme LLC | $17.85 | 2022 | |
| Acadia Pharmaceuticals INC | $17.57 | 2022 | |
| Currax Pharmaceuticals LLC | $15.21 | 2022 | |
| Galt Pharmaceuticals, LLC | $4.86 | 2023 | Orphengesic Forte |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.